Immunotherapy, cancer and PET.

Autor: Simó-Perdigó M; Servicio de Medicina Nuclear, Hospital Universitario Vall de Hebrón, Barcelona, España; Grupo de Oncología de la SEMNIM. Electronic address: marc.simo@quironsalud.es., Vercher-Conejero JL; Servicio de Medicina Nuclear, Unidad PET, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, España; Grupo de Oncología de la SEMNIM., Viteri S; Instituto Oncológico Dr. Rosell, CM Teknon, Grupo QuironSalud, Barcelona, España; Grupo de Oncología de la SEMNIM., García-Velloso MJ; Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España; Grupo de Oncología de la SEMNIM.
Jazyk: English; Spanish; Castilian
Zdroj: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2021 Mar-Apr; Vol. 40 (2), pp. 123-135. Date of Electronic Publication: 2021 Mar 02.
DOI: 10.1016/j.remn.2021.02.001
Abstrakt: The treatment of cancer by immunotherapy has been a revolution, as it is the first strategy that manages to control the disease for prolonged periods of time. Its efficacy is associated with different imaging response patterns and the appearance of new toxicities. We would highlight two patterns of tumour response: pseudoprogression, or growth of tumour lesions after the start of immunotherapy treatment, followed by a significant reduction in lesions, and hyperprogression, acceleration of tumour progression and metastasis early after the start of treatment. The emergence of such patterns has generated new metabolic response criteria, such as PECRIT, PERCIMT, imPERCIST and IPERCIST. Of particular interest are the new immunoPET-specific biomarkers, as they allow the identification of patients presenting the tumour target and are useful for predicting response to immunotherapy.
(Copyright © 2021 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: